image: Journal of Child and Adolescent Psychopharmacology (JCAP) is an authoritative peer-reviewed journal published 10 times a year online with Open Access options and in print. The Journal, celebrating 25 years in 2015, is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the JCAP website. view more
Credit: ©Mary Ann Liebert, Inc., publishers
New Rochelle, NY, April 20, 2015--A new study of families participating in a clinical trial to treat children with severe physical aggression explored the factors affecting parent satisfaction with the research study. Parents' overall satisfaction with the clinical trial experience and the relationship between the parent satisfaction and their child's treatment group or response to therapy are reported in an article in Journal of Child and Adolescent Psychopharmacology (JCAP), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, and is available free on the JCAP website until May 20, 2015.
The article "Participant Satisfaction in a Study of Stimulant, Parent Training, and Risperidone in Children with Severe Physical Aggression" presents a study by E. Victoria Rundberg-Rivera, MD and coauthors from Stony Brook University School of Medicine (NY), Johns Hopkins University, Bloomberg School of Public Health, and Kennedy Krieger Institute (Baltimore, MD), Center for Psychiatry and Behavioral Medicine in Las Vegas (NV), Ohio State University (Columbus), DePelchin Children's Center (Houston, TX), University of Pittsburgh School of Medicine (PA), and Case Western Reserve University (Cleveland, OH). The Treatment of Severe Childhood Aggression (TOSCA) study included behavioral management training for parents of children with severe physical aggression, disruptive behavior disorder, or attention-deficit/hyperactivity disorder. The children all received a psychostimulant and either a placebo or the antipsychotic drug risperidone.
"These findings indicate high levels of satisfaction with TOSCA study involvement and, taken together with previous pediatric psychopharmacology social validity studies, suggest high levels of support for the research experience," according to the authors. "These findings may inform research bioethics and may have implications for the deliberations of institutional review boards."
###
About the Journal
Journal of Child and Adolescent Psychopharmacology (JCAP) is an authoritative peer-reviewed journal published 10 times a year online with Open Access options and in print. The Journal, celebrating 25 years in 2015, is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the JCAP website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Journal
Journal of Child and Adolescent Psychopharmacology